| Literature DB >> 20567637 |
Chin Lin1, Colin Edwards, Guy P Armstrong, Anthony Scott, Hitesh Patel, Hamish Hart, Jonathan P Christiansen.
Abstract
CONDENSED ABSTRACT: The prevalence and prognostic importance of CM occurring as a consequence of AF is poorly defined. This study investigated the incidence of CM in patients with AF, its clinical features and long-term outcomes. We demonstrated that CM is common in patients presenting acutely with newly diagnosed rapid AF, and carries a worse long-term prognosis. Systolic dysfunction was reversible in an important proportion of patients, suggesting a greater prevalence of rate-related CM in AF than has previously been postulated. This underscores the importance of appropriate rhythm management strategies and repeat imaging studies.Entities:
Keywords: atrial fibrillation; cardiomyopathy; prevalence; prognosis
Year: 2010 PMID: 20567637 PMCID: PMC2884341 DOI: 10.4137/cmc.s4106
Source DB: PubMed Journal: Clin Med Insights Cardiol ISSN: 1179-5468
Baseline characteristics of the study cohort.
| Number of patients | 69 | 207 |
| Patient Characteristics (n,%): | ||
| Age (years) (Mean ± SD) | 72 ± 11 | 72 ± 13 |
| Sex (Male%) | 67% | 48% |
| Known Cardiomyopathy | 9 (13%) | 7 (3%) |
| Ischaemic Heart Disease | 28 (41%) | 60 (29%) |
| Hypertension | 30 (43%) | 90 (44%) |
| Valvular Heart Disease | 7 (10%) | 25 (12%) |
| Primary symptom on admission (Mean ± SD) | ||
| Palpitations | 23 (33%) | 127 (61%) |
| Breathlessness | 50 (72%) | 97 (47%) |
| Chest pain | 19 (28%) | 80 (39%) |
| Clinical findings on admission | ||
| Resting heart rate (Mean ± SD) | 141 ± 19 | 132 ± 23 |
| Hypotension (BP < 100 mmHg systolic) | 7 (10%) | 11 (5%) |
| Medication at discharge (n,%): | ||
| Beta-blockers | 44 (64%) | 123 (59%) |
| Calcium channel blockers | 37 (54%) | 96 (46%) |
| Digoxin | 34 (49%) | 49 (24%) |
| Amiodarone | 15 (22%) | 48 (23%) |
| Class I antiarrhythmic | 1 (1%) | 13 (6%) |
| Aspirin | 47 (68%) | 132 (64%) |
| Warfarin | 43 (62%) | 98 (47%) |
Values are means ± SD, or numbers of patients (percentages).
*p < 0.05.
Echocardiography results.
| Echocardiography data on admission (Mean ± SD) | ||
| LVEDD (cm) | 5.7 ± 0.9 | 5.2 ± 3.3 |
| LVESD (cm) | 4.5 ± 0.9 | 3.2 ± 1.7 |
| Ejection Fraction (%) | 37 ± 11 | 67 ± 8 |
| LA Size (cm) | 4.6 ± 0.9 | 4.3 ± 0.8 |
| Echocardiography data at 6 months (Mean ± SD) | ||
| LVEDD (cm) | 5.7 ± 0.7 | 5.0 ± 1.0 |
| LVESD (cm) | 3.9 ± 0.8 | 3.4 ± 0.9 |
| Ejection Fraction (%) | 53 ± 12 | 62 ± 13 |
| LA Size (cm) | 4.4 ± 0.8 | 4.5 ± 0.6 |
Values are means ± SD, or numbers of patients (percentages).
*p < 0.05.
Figure 1Graphical representation of the index and follow-up EF for all 26 patients of the initial 60 with newly diagnosed CM who underwent follow-up echocardiography, confirming that nearly all made significant gains in systolic function. Note that 13 (50%) normalised their EF.
Figure 2Kaplan-Meier analysis showing the significantly worse mortality (p < 0.05) in those patients with newly diagnosed CM in the setting of acute AF and tachycardia, as compared with patient with no CM.